Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis

References

• Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. In: Advances in experimental medicine and biology. Springer New York LLC; 2019;1165:3–15.
   Google Scholar
• Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dialysis Transplantation. 2014;29(1):29–40.
   PubMed Web of Science ®Google Scholar
• Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127(5):569–574.
   PubMed Web of Science ®Google Scholar
• Massicotte-Azarniouch D, Kuwornu JP, Carrero JJ, et al. Incident atrial fibrillation and the risk of congestive heart failure, myocardial infarction, end-stage kidney disease, and mortality among patients with a decreased estimated GFR. Am J Kidney Dis. 2018;71(2):191–199.
   PubMed Web of Science ®Google Scholar
• Molnar AO, Bota SE, McArthur E, et al. Risk and complications of venous thromboembolism in dialysis patients. Nephrol Dial Transplant. 2018;33(5):874–880.
   PubMed Web of Science ®Google Scholar
• Matusik PT, Heleniak Z, Papuga-Szela E, et al. Chronic kidney disease and its impact on a prothrombotic state in patients with atrial fibrillation. J Clin Med. 2020;9(8):2476.
   Web of Science ®Google Scholar
• Alhousani M, Malik SU, Abu-Hashyeh A, et al. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2021;198:103–114.
   PubMed Web of Science ®Google Scholar
• Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774–782.
   PubMed Web of Science ®Google Scholar
• Randhawa MS, Vishwanath R, Rai MP, et al. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. JAMA Network Open. 2020;3(4):e202175.
   PubMed Web of Science ®Google Scholar
• Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–2484.
   PubMed Web of Science ®Google Scholar
• Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation focus on non-vitamin k antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209–218.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the Aristotle randomized clinical trial. JAMA Cardiol. 2016;1(4):451–460.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized evaluation of long-term anticoagulation therapy) trial analysis. Circulation. 2014;129(9):961–970.
   PubMed Web of Science ®Google Scholar
• Gu ZC, Kong LC, Wei AH, et al. Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase III clinical trials. Cardiovasc Diagn Ther. 2019;9(5):410–419.
   PubMed Web of Science ®Google Scholar
• See LC, Lee HF, Chao TF, et al. Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis: a population-based cohort study and meta-analysis. Cardiovasc Drugs Ther. 2020. DOI: 10.1007/s10557-020-07108-4.
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Roetker NS, Yan H, et al. Direct-acting oral anticoagulants versus warfarin in medicare patients with chronic kidney disease and atrial fibrillation. Stroke. 2020;51(8):2364–2373.
   PubMed Web of Science ®Google Scholar
• Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J. 2020;223:3–11.
   PubMed Web of Science ®Google Scholar
• Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-world setting comparison of nonvitamin-k antagonist oral anticoagulants versus vitamin-k antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48(9):2494–2503.
   PubMed Web of Science ®Google Scholar
• Ha JT, Neuen BL, Cheng LP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease. Ann Intern Med. 2019;171(3):181–189.
   PubMed Web of Science ®Google Scholar
• Andò G, Non-vitamin CP. K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis. Int J Cardiol. 2017;231:162–169.
   PubMed Web of Science ®Google Scholar
• Kimachi M, Furukawa TA, Kimachi K, et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;11:2017.
   Web of Science ®Google Scholar
• Malhotra K, Ishfaq MF, Goyal N, et al. Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis. Neurology. 2019;92(21):e2421–31.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Levey AS, De Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies conference report. Kidney Int. 2011;80(1):17–28.
   PubMed Web of Science ®Google Scholar
• Kim SY, Park JE, Lee YJ, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66(4):408–414.
   PubMed Web of Science ®Google Scholar
• Lee KH, Park HW, Cho JG, et al. Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction. Europace. 2015;17(suppl 2):ii69–75.
   PubMedGoogle Scholar
• Loo SY, Coulombe J, Dell’Aniello S, et al. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ Open. 2018;8(1):8.
   Web of Science ®Google Scholar
• Laugesen EK, Staerk L, Carlson N, et al. Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study. Thromb J. 2019;17:17.
   PubMed Web of Science ®Google Scholar
• Makani A, Saba S, Jain SK, et al. Safety and efficacy of direct oral anticoagulants versus warfarin in patients with chronic kidney disease and atrial fibrillation. Am J Cardiol. 2020;125(2):210–214.
   PubMed Web of Science ®Google Scholar
• Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519–1529.
   PubMed Web of Science ®Google Scholar
• Ashley J, McArthur E, Bota S, et al. Risk of cardiovascular events and mortality among elderly patients with reduced GFR receiving direct oral anticoagulants. Am J Kidney Dis. 2020;76(3):311–320.
   PubMed Web of Science ®Google Scholar
• Bonnemeier H, Huelsebeck M, Kloss S. Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany – a retrospective cohort study. Int J Cardiol Heart Vasc. 2019;23:100367.
   PubMed Web of Science ®Google Scholar
• Yuzawa Y, Kuronuma K, Okumura Y, et al. Relationship between the renal function and adverse clinical events in patients with atrial fibrillation: a Japanese multicenter registry substudy. J Clin Med. 2020;9(1):167.
   Web of Science ®Google Scholar
• Shin JI, Secora A, Caleb Alexander G, et al. Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation. Clin J Am Soc Nephrol. 2018;13(8):1144–1152.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med. 2019;132(9):1078–1083.
   PubMed Web of Science ®Google Scholar
• Heleniak Z, Papuga-Szela E, Krzysztof P, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease stage G4: a single-center experience. J Cardiovasc Pharmacol. 2020;76(6):671–677.
   PubMed Web of Science ®Google Scholar
• Weir MR, Berger JS, Ashton V, et al. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. Curr Med Res Opin. 2017;33(10):1891–1900.
   PubMed Web of Science ®Google Scholar
• Leshnower BG, Guyton RA, Puskas JD. Why randomized clinical trials are important to cardiac surgeons. Current Opinion in Cardiol. 2011;26(6):536–540.
   PubMed Web of Science ®Google Scholar
• Hordijk-Trion M, Lenzen M, Wijns W, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006;27(6):671–678.
   PubMed Web of Science ®Google Scholar
• Smyth B, Haber A, Trongtrakul K, et al. Representativeness of randomized clinical trial cohorts in end-stage kidney disease: a meta-analysis. JAMA Intern Med. 2019;179(10):1316–1324.
   PubMed Web of Science ®Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence – what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297.
   PubMed Web of Science ®Google Scholar
• Takagi H, Goto SN, Watanabe T, et al. A meta-analysis of adjusted hazard ratios from 20 observational studies of bilateral versus single internal thoracic artery coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2014;148(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, Jjv M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Shen JI, Montez-Rath ME, Lenihan CR, et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2015;66(4):677–688.
   PubMed Web of Science ®Google Scholar
• Pokorney S. RENal hemodialysis patients allocated apixaban versus warfarin in atrial fibrillation - American College of Cardiology. American Heart Association annual scientific sessions. Philadelphia; 2019. [cited 2021 Feb 4]. Available from: https://www.acc.org/latest-in-cardiology/clinical-trials/2019/11/15/17/29/renal-af#references-for-article
   Google Scholar
• Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, et al. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis. Pacing Clin Electrophysiol. 2018;41:627–634.
   PubMed Web of Science ®Google Scholar
• George A, Stead TS, Ganti L. What’s the risk: differentiating risk ratios, odds ratios, and hazard ratios? Cureus. 2020;12.
   Web of Science ®Google Scholar